Article
NCCN Unveils Value Tool for CML and MM
Author(s):
NCCN Evidence Blocks add affordability to Guidelines recommendations on safety, efficacy, quality, and consistency of regimens.
At its 10th Annual Congress on Hematological Malignancies, the National Comprehensive Cancer Network (NCCN) provided details of the NCCN Evidence Blocks for chronic myelogenous leukemia (CML) and multiple myeloma (MM). The announcement of this value calculator had created ripples back in August when it followed the release of ASCO’s Value Framework and the DrugAbacus tool developed by Peter Bach, MD, and his team at the Memorial Sloan Kettering Cancer Center.
"NCCN Evidence Blocks will educate providers and patients about the efficacy, safety, and affordability of systemic therapy, serving as a starting point for shared decision-making based on the individual patient's value system," said Robert W. Carlson, MD, chief executive officer, NCCN.
Read the press release.
